Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Gross Margin (2016 - 2025)

Historic Gross Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 56.02%.

  • Anika Therapeutics' Gross Margin fell 96400.0% to 56.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.74%, marking a year-over-year decrease of 200700.0%. This contributed to the annual value of 63.38% for FY2024, which is 49400.0% down from last year.
  • Anika Therapeutics' Gross Margin amounted to 56.02% in Q3 2025, which was down 96400.0% from 50.9% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Gross Margin ranged from a high of 66.69% in Q2 2024 and a low of 199.14% during Q4 2023
  • In the last 5 years, Anika Therapeutics' Gross Margin had a median value of 58.23% in 2021 and averaged 35.33%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -1860700bps in 2022, then surged by 2551000bps in 2024.
  • Anika Therapeutics' Gross Margin (Quarter) stood at 50.62% in 2021, then tumbled by -368bps to 135.45% in 2022, then tumbled by -47bps to 199.14% in 2023, then surged by 128bps to 55.96% in 2024, then rose by 0bps to 56.02% in 2025.
  • Its Gross Margin stands at 56.02% for Q3 2025, versus 50.9% for Q2 2025 and 56.1% for Q1 2025.